Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer
Antonio Jimeno, Aik Choon Tan, Jordy Coffa et al. · Cancer Research · 2008
The epidermal growth factor receptor (EGFR) inhibitor erlotinib is approved for treatment of pancreatic cancer but the overall activity is minimal, and known predictive factors for EGFR inhibitor efficacy are infrequent in this disease. We tested the hypothesis that global activation of the EGFR pathway is predictive of EGFR inhibitor efficacy. Pancreatic cancer tumors directly xenografted at surgery were treated with the EGFR inhibitors erlotinib and cetuximab and analyzed for biological features. Two of 10 tumors were sensitive, and by global gene expression profiling with gene set enrichment analysis, the EGFR pathway was highly expressed in sensitive compared with resistant tumors. The core gene components driving EGFR pathway overexpression were pathway ligands and positive effectors. In a prospective validation, the EGFR pathway-based signature correctly predicted anti-EGFR treatment response in eight additional tumors and was not predictive of response to gemcitabine and CI1040 (a MEK inhibitor). Analysis of EGFR, KRAS, and PIK3CA mutations and gene amplification by fluorescence in situ hybridization and multiplex ligation-dependent probe amplification showed that none of these genetic abnormalities were neither predictive nor responsible for the EGFR pathway activation. Coordinated overexpression of the EGFR pathway predicts susceptibility to EGFR inhibitors in pancreatic cancer. These results suggest a phenomenon of pathway addiction and support the value of unbiased system biology approaches in drug development.
Cited by 92 works. doi:10.1158/0008-5472.can-07-5200
Authors
- Antonio Jimeno
- Aik Choon Tan
- Jordy Coffa
- N.V. Rajeshkumar
- Peter Kulesza
- Belén Rubio‐Viqueira
- Jenna Wheelhouse
- Begoña Diosdado
- Wells A. Messersmith
- Christine A. Iacobuzio–Donahue
- Anirban Maitra
- Marileila Varella‐Garcia
- Fred R. Hirsch
- Gerrit A. Meijer
- Manuel M. Hidalgo
References
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
- The Hallmarks of Cancer
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
- A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
- PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- The Consensus Coding Sequences of Human Breast and Colorectal Cancers